July 16, 2024

Osteoporosis Treatment Market is driven by increasing geriatric population globally

Osteoporosis, commonly known as brittle bone disease, is a condition where the density and quality of bone are reduced, leading to an increased risk of fractures. Some of the key factors responsible for the onset of osteoporosis include lack of physical activity, menopause, vitamin D and calcium deficiency, family history of osteoporosis, and excessive alcohol consumption. The most commonly prescribed drugs for osteoporosis treatment include bisphosphonates, parathyroid hormone therapy, estrogen/hormone therapy, rank ligand inhibitors, and selective estrogen receptor modulators. These drugs aim to increase bone mineral density and reduce the risk of fractures by inhibiting bone resorption. The rising prevalence of osteoporosis owing to rapidly aging population globally is driving significant demand for osteoporosis treatment drugs. According to the International Osteoporosis Foundation, globally one in three women and one in five men over the age of 50 years will experience osteoporotic fractures in their lifetime.

The global Osteoporosis Treatment Market is estimated to be valued at US$ 14.01 billion in 2023 and is expected to exhibit a CAGR of 3.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
One of the major market trends is the shift towards bone-forming osteoporosis drugs, or anabolics. Traditionally, anti-resorptive drugs such as bisphosphonates were the mainstay of treatment. However, anabolic drugs work by stimulating new bone formation instead of just slowing bone resorption. Teriparatide recombinant human parathyroid hormone and abaloparatide are two approved anabolic drugs. Their superior ability to increase bone mineral density compared to anti-resorptives has increased adoption rate in clinical practice.

Another notable trend is the increase in pipeline drugs for novel drug delivery mechanisms. For example, several oral RANK ligand inhibitors are under development offering once daily oral dosing over current osteoporosis injectables. Additionally, research into peptides that mimic the bone-building effects of PTH without the safety concerns associated with current therapies can further expand treatment options.

Porter’s Analysis
Threat of new entrants: The osteoporosis treatment market requires extensive R&D and significant capital investments, lowering the threat of new entrants.
Bargaining power of buyers: Individual customers have little bargaining power due to lack of treatment alternatives. However, large buyers like hospitals can negotiate lower drug prices.
Bargaining power of suppliers: Presence of many drug manufacturers limits the bargaining power of suppliers of raw materials and pharmaceutical intermediates.
Threat of new substitutes: Alternative treatment options remain limited due to complexity of bone health, maintaining supplier bargaining power at moderate levels.
Competitive rivalry: The market is dominated by large pharmaceutical companies investing heavily in R&D and marketing of branded drugs, facing strong competition.

Key Takeaways

The global osteoporosis treatment market is expected to witness high growth over the forecast period. Regional analysis: Europe is also a major market for osteoporosis treatment due to growing geriatric population suffering from the disease. Asia Pacific is anticipated to witness fastest growth between 2023-2030 as healthcare infrastructure and access to treatment improves.

Key players: Key players operating in the osteoporosis treatment market are Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy’s Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co., Inc., GSK plc., and Pfizer Inc. They are focusing on developing advanced drugs for treatment.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it